Retigabine (also known as ezogabine) is a synthetic organic compound (CAS 150812-12-7, C₁₆H₁₈FN₃O₂) that was used as an anticonvulsant medication for partial-onset seizures in adults. It acts as a potassium channel opener (Kv7/KCNQ activator), stabilizing neuronal activity. Marketed as Treziba/Potiga, it was discontinued worldwide in 2017 due to serious side effects including retinal pigmentation, blue skin discoloration, dizziness, fatigue, and urinary retention. Now available for research purposes, such as in epilepsy models, neuropathic pain studies, and ion channel research.